Your browser doesn't support javascript.
loading
Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer.
Wang, Shidan; Rong, Ruichen; Yang, Donghan M; Fujimoto, Junya; Bishop, Justin A; Yan, Shirley; Cai, Ling; Behrens, Carmen; Berry, Lynne D; Wilhelm, Clare; Aisner, Dara; Sholl, Lynette; Johnson, Bruce E; Kwiatkowski, David J; Wistuba, Ignacio I; Bunn, Paul A; Minna, John; Xiao, Guanghua; Kris, Mark G; Xie, Yang.
Afiliación
  • Wang S; Quantitative Biomedical Research Center, The Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Rong R; Quantitative Biomedical Research Center, The Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Yang DM; Quantitative Biomedical Research Center, The Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Fujimoto J; Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bishop JA; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Yan S; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Cai L; Quantitative Biomedical Research Center, The Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Behrens C; Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Berry LD; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Wilhelm C; Department of Thoracic Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Aisner D; Department of Pathology, University of Colorado, Denver, Colorado, USA.
  • Sholl L; Department of Pathology, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.
  • Johnson BE; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Kwiatkowski DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard University, Boston, Massachusetts, USA.
  • Wistuba II; Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bunn PA; Division of Medical Oncology, School of Medicine, University of Colorado, Aurora, Colorado, USA.
  • Minna J; Hamon Center for Therapeutic Oncology Research.
  • Xiao G; Departments of Internal Medicine and Pharmacology.
  • Kris MG; Simmons Comprehensive Cancer Center, and.
  • Xie Y; Quantitative Biomedical Research Center, The Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
J Clin Invest ; 133(2)2023 01 17.
Article en En | MEDLINE | ID: mdl-36647832
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Invest Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fosfatidilinositol 3-Quinasas / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Invest Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos